ArticleArchives of osteoporosis2026
Burden and temporal trends attributable to low bone mineral density in Mexico, 1990-2023: a global burden of disease analysis.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low bone mineral density contributes to fractures and injury-related disability. Using Global Burden of Disease 2023 estimates for Mexico (1990-2023), we found rising total burden but declining age-standardised rates, with disability becoming increasingly important and a recent uptick in non-fatal outcomes. Strengthening fracture prevention is needed in ageing populations.
backgroundLow bone mineral density (LBMD) is a modifiable risk factor for fractures and other injury-related outcomes; however, contemporary national estimates for Mexico remain limited, constraining policy planning and prevention priorities.
methodsWe conducted a secondary analysis of Mexico-specific Global Burden of Disease (GBD) 2023 estimates obtained from the IHME GBD Results Platform for adults aged ≥ 40 years from 1990 to 2023. We summarised all-age counts and age-standardised rates (ASRs) per 100,000 for deaths, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs). Population exposure to LBMD was assessed using the summary exposure value (SEV). Temporal trends were evaluated using joinpoint regression, reporting annual percentage change (APC) and average APC (AAPC) with 95% CIs.
resultsFrom 1990 to 2023, all-age deaths increased from 2,962.99 to 4,042.72 and DALYs from 183,439.82 to 344,078.31, driven mainly by rising YLDs (116,520.80 to 255,652.37). Despite rising counts, ASRs declined: the age-standardised death rate decreased from 7.41 to 3.06 per 100,000, and the age-standardised DALY rate decreased from 422.13 to 247.52. Overall, AAPCs indicated sustained declines for mortality (- 2.7%) and YLLs (- 2.5%), while DALYs decreased more modestly (AAPC - 1.6%), with a recent post-2020 increase in DALYs (APC 3.7%/year) and YLDs (APC 5.2%/year). SEV decreased modestly from 20.80 in 1990 to 18.78 in 2023 and remained consistently higher in females than males. In descriptive time-series analyses, the Sociodemographic Index showed inverse co-movement with LBMD-attributable ASRs (mortality rₛ = - 0.998; DALYs rₛ = - 0.994; YLLs rₛ = - 0.999; YLDs rₛ = - 0.950; all p < 0.001).
conclusionsMexico experienced rising absolute LBMD-attributable burden alongside declining age-standardised rates, with disability becoming increasingly prominent. These findings support strengthening fracture risk assessment, fall-prevention strategies, and post-fracture secondary prevention among Mexico's ageing population.
Indexed as
Identifiers
42599598What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.